Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression
ConclusionLRG may activate and inhibit the AMPK and AKT pathways, respectively, and decrease FTO expression, thereby alleviating abdominal obesity in type 2 diabetes.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Obesity | Study | Victoza